Telomir Pharmaceuticals, Inc. Common Stock
TELOHealthcare|Biotechnology|US
$0.71
-0.07 (-8.97%)
DCF Value
$0.20
Tangible Book / Share
$0.06
Cash / Share
$0.07
Financials
Financial Snapshot
Market Cap
$52.3M
Enterprise Value
$47.8M
Revenue (TTM)
$0.00
Net Income (TTM)
-$5.5M
Cash & Investments
$4.5M
Net Cash
$4.5M
Free Cash Flow (TTM)
-$4.6M
Operating CF (TTM)
-$4.6M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$4.5M
Quarterly Burn
$1.1M
Monthly Burn
$381.1K
Est. Runway
~3.9 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $1.4K | $1.2K | $1.3M | $7.3M | $4.5M | |
| Operating Cash Flow | -$119.4K | -$468.7K | -$3.9M | -$5.1M | -$3.7M | -$4.6M | |
| Free Cash Flow | -$119.4K | -$468.7K | -$3.9M | -$5.1M | -$3.7M | -$4.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$4.00 | $0.00 | $0.00 | -$3.00 | |
| Financing Cash Flow | $119.4K | $470.1K | $3.9M | $6.3M | $9.7M | $1.8M |
R&D Spending
R&D (TTM)
$2.5M
R&D Intensity
—
R&D Growth vs Prior
+1.0%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $126.5K | $833.2K | $1.6M | $2.2M | $2.4M | $2.5M | |
| SG&A | $11.6K | $20.9K | $600.2K | $9.6M | $8.1M | $3.2M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $126.5K | $833.2K | $1.6M | $2.2M | $2.4M | $2.5M | |
| SG&A | $11.6K | $20.9K | $600.2K | $9.6M | $8.1M | $3.2M | |
| Operating Income | -$138.1K | -$854.1K | -$3.9M | -$12.2M | -$10.5M | -$4.9M | |
| Interest Expense | $0.00 | $0.00 | $1.6M | -$4.3M | $0.00 | $2.4K | |
| Pretax Income | -$138.1K | -$854.1K | -$13.1M | -$16.5M | -$10.4M | -$5.5M | |
| Net Income | -$138.1K | -$854.1K | -$13.1M | -$16.5M | -$10.4M | -$5.5M | |
| EPS (Diluted) | -0.00 | -0.03 | -0.44 | -0.56 | -0.33 | -1.49 | |
| EBITDA | $0.00 | $0.00 | -$11.4M | -$7.9M | -$10.4M | -$4.8M | |
| Shares Out. (M) | 29.61 | 29.61 | 29.61 | 29.54 | 31.65 | 68.77 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $1.4K | $1.2K | $1.3M | $7.3M | $4.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $0.00 | $1.4K | $435.2K | $1.3M | $7.3M | $4.6M | |
| Total Assets | $55.0K | $48.7K | $4.8M | $1.3M | $7.3M | $4.6M | |
| Total Current Liabilities | $138.1K | $986.0K | $1.3M | $681.0K | $1.4M | $236.7K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $138.1K | $986.0K | $1.3M | $681.0K | $1.4M | $236.7K | |
| Stockholders' Equity | -$83.1K | -$937.3K | $3.4M | $643.0K | $5.9M | $4.4M | |
| Retained Earnings | -$138.1K | -$992.3K | -$14.1M | -$30.6M | -$41.0M | -$44.4M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$119.4K | -$468.7K | -$3.9M | -$5.1M | -$3.7M | -$4.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$4.00 | $0.00 | $0.00 | -$3.00 | |
| Free Cash Flow | -$119.4K | -$468.7K | -$3.9M | -$5.1M | -$3.7M | -$4.6M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $119.4K | $470.1K | $3.9M | $6.3M | $9.7M | $1.8M | |
| Issuance of Stock | $0.00 | $0.00 | $1.0M | $6.8M | $9.6M | $1.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $462.4K | $3.2M | -$101.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $6.9M | $5.3M | $303.9K | |
| Net Change in Cash | $0.00 | $1.4K | -$188.00 | $1.3M | $6.0M | -$2.8M |
Dilution Tracker
Shares Outstanding
74M
5-Year Share Growth
+6.9%
Stock Issuance (TTM)
$1.0M
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 29.61 | 29.61 | 29.61 | 29.54 | 31.65 | 68.77 | |
| Change vs Prior % | — | 0.0% | 0.0% | -0.2% | 7.2% | 117.3% | |
| Stock Issuance | $0.00 | $0.00 | $1.0M | $6.8M | $9.6M | $1.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $6.9M | $5.3M | $303.9K |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 166.2% | 91.1% | -380.2% | -2571.0% | -176.1% | -107.9% | |
| ROA % | -251.1% | -1752.8% | -273.8% | -1248.7% | -141.8% | -118.0% | |
| ROIC % | -380.9% | 91.1% | -111.4% | -1662.3% | -165.0% | -112.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -518.4% | -361.5% | -210.6% | 13.9% | |
| Net Income | 0.0% | -518.4% | -1430.4% | -26.5% | 37.0% | |
| EPS (Diluted) | 0.0% | -512.8% | -1427.8% | -27.3% | 41.1% | |
| Operating Cash Flow | 0.0% | -292.5% | -723.6% | -31.4% | 27.3% | |
| Free Cash Flow | 0.0% | -292.5% | -723.6% | -31.4% | 27.3% | |
| R&D Expense | 0.0% | 558.7% | 88.9% | 42.0% | 9.0% | |
| SG&A Expense | 0.0% | 79.9% | 2766.1% | 1505.5% | -15.9% | |
| Total Assets | 0.0% | -11.4% | 9696.4% | -72.3% | 454.5% | |
| Book Value / Share | 0.0% | -1027.5% | 466.8% | -81.3% | 758.2% | |
| Debt | 0.0% | -100.0% | 0.0% | -7.5% | 407.1% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -0.2% | 7.2% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B11.09
10Y Low / Med / High7.12 / 60.28 / 189.26
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.20
Tangible Book / Share
$0.06
Net Current Assets / Share
$0.06
Graham Net-Net
$0.06
Cash / Share
$0.07
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | -1489.36 | -243.06 | -15.91 | -7.36 | -4.03 | -0.48 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -2493.28 | -221.14 | 60.28 | 189.26 | 7.12 | 11.09 | |
| EV/EBITDA | 0.00 | 0.00 | -18.14 | -15.34 | -3.39 | -10.02 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
116.94
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.5M | $0.00 | $0.00 |
| Net Income | -$3.5M | -$5.4M | -$8.2M |
| EPS | $-0.11 | $-0.17 | $-0.26 |
| # Analysts (EPS) | 1 | 1 | 1 |